HLA B*44: Protective Effects in MS Susceptibility and MRI Outcome Measures

Overview

Journal Neurology

Specialty Neurology

Date 2010 Aug 18

PMID 20713950

Citations 31

Authors

B C Healy

M Liguori

D Tran

T Chitnis

B Glanz

C Wolfish

S Gauthier

G Buckle

M Houtchens

L Stazzone

S Khoury

R Hartzmann

M Fernandez-Vina

D A Hafler

H L Weiner

C R G Guttmann

P L De Jager

Affiliations

Soon will be listed here.

Abstract

Objective: In addition to the main multiple sclerosis (MS) major histocompatibility complex (MHC) risk allele (HLA DRB1*1501), investigations of the MHC have implicated several class I MHC loci (HLA A, HLA B, and HLA C) as potential independent MS susceptibility loci. Here, we evaluate the role of 3 putative protective alleles in MS: HLA A*02, HLA B*44, and HLA C*05.

Methods: Subjects include a clinic-based patient sample with a diagnosis of either MS or a clinically isolated syndrome (n = 532), compared to subjects in a bone marrow donor registry (n = 776). All subjects have 2-digit HLA data. Logistic regression was used to determine the independence of each allele's effect. We used linear regression and an additive model to test for correlation between an allele and MRI and clinical measures of disease course.

Results: After accounting for the effect of HLA DRB1*1501, both HLA A*02 and HLA B*44 are validated as susceptibility alleles (p(A*02) 0.00039 and p(B*44) 0.00092) and remain significantly associated with MS susceptibility in the presence of the other allele. Although A*02 is not associated with MS outcome measures, HLA B*44 demonstrates association with a better radiologic outcome both in terms of brain parenchymal fraction and T2 hyperintense lesion volume (p = 0.03 for each outcome).

Conclusion: The MHC class I alleles HLA A*02 and HLA B*44 independently reduce susceptibility to MS, but only HLA B*44 appears to influence disease course, preserving brain volume and reducing the burden of T2 hyperintense lesions in subjects with MS.

Citing Articles

Clinical Phenotype of HLA B*44 Patients in a Rheumatology Outpatient Clinic Favors Peripheral Arthropathies.

Aljinovic J, Soso D, Petric M, Perkovic D, Marasovic Krstulovic D, Kero D J Clin Med. 2024; 13(18).

PMID: 39336927 PMC: 11432423. DOI: 10.3390/jcm13185440.

Multi-Omics Integration Analysis Pinpoint Proteins Influencing Brain Structure and Function: Toward Drug Targets and Neuroimaging Biomarkers for Neuropsychiatric Disorders.

Wang Y, Zhang S, Gong W, Liu X, Mo Q, Shen L Int J Mol Sci. 2024; 25(17).

PMID: 39273172 PMC: 11395524. DOI: 10.3390/ijms25179223.

Association of HLA-A, B, and C alleles and cancer susceptibility in 179 solid malignancies.

Carabano M, Liu T, Liu A, Lee J, Cheng L, Wang L Am J Transl Res. 2023; 15(9):5642-5652.

PMID: 37854217 PMC: 10579009.

Genetic Basis of Inflammatory Demyelinating Diseases of the Central Nervous System: Multiple Sclerosis and Neuromyelitis Optica Spectrum.

Ortiz G, Torres-Mendoza B, Ramirez-Jirano J, Marquez-Pedroza J, Hernandez-Cruz J, Mireles-Ramirez M Genes (Basel). 2023; 14(7).

PMID: 37510224 PMC: 10379341. DOI: 10.3390/genes14071319.

In silico prioritisation of microRNA-associated common variants in multiple sclerosis.

Fashina I, McCoy C, Furney S Hum Genomics. 2023; 17(1):31.

PMID: 36991503 PMC: 10061723. DOI: 10.1186/s40246-023-00478-4.

References

Bergamaschi L, Leone M, Fasano M, Guerini F, Ferrante D, Bolognesi E . HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes Immun. 2009; 11(2):173-80. PMC: 2834350. DOI: 10.1038/gene.2009.101. View

Silva A, Bettencourt A, Pereira C, Santos E, Carvalho C, Mendonca D . Protective role of the HLA-A*02 allele in Portuguese patients with multiple sclerosis. Mult Scler. 2009; 15(6):771-4. DOI: 10.1177/1352458509104588. View

Smestad C, Brynedal B, Jonasdottir G, Lorentzen A, Masterman T, Akesson E . The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol. 2007; 14(8):835-40. DOI: 10.1111/j.1468-1331.2007.01825.x. View

Liu L, Meier D, Polgar-Turcsanyi M, Karkocha P, Bakshi R, Guttmann C . Multiple sclerosis medical image analysis and information management. J Neuroimaging. 2005; 15(4 Suppl):103S-117S. DOI: 10.1177/1051228405282864. View

Vacek M, Schaffer A, Davis J, Fischer R, Dale J, Adams S . HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia). Clin Immunol. 2005; 118(1):59-65. DOI: 10.1016/j.clim.2005.09.006. View

Meier D, Guttmann C . MRI time series modeling of MS lesion development. Neuroimage. 2006; 32(2):531-7. DOI: 10.1016/j.neuroimage.2006.04.181. View

Ramagopalan S, Morris A, Dyment D, Herrera B, DeLuca G, Lincoln M . The inheritance of resistance alleles in multiple sclerosis. PLoS Genet. 2007; 3(9):1607-13. PMC: 1971120. DOI: 10.1371/journal.pgen.0030150. View

Yeo T, De Jager P, Gregory S, Barcellos L, Walton A, Goris A . A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol. 2007; 61(3):228-36. PMC: 2737610. DOI: 10.1002/ana.21063. View

Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A . Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol. 2009; 209(1-2):123-30. DOI: 10.1016/j.jneuroim.2009.01.023. View

10.

Brynedal B, Duvefelt K, Jonasdottir G, Roos I, Akesson E, Palmgren J . HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One. 2007; 2(7):e664. PMC: 1919434. DOI: 10.1371/journal.pone.0000664. View

11.

Hauser S, Oksenberg J . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006; 52(1):61-76. DOI: 10.1016/j.neuron.2006.09.011. View

12.

Wei X, Warfield S, Zou K, Wu Y, Li X, Guimond A . Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging. 2002; 15(2):203-9. DOI: 10.1002/jmri.10053. View

13.

Chao M, Barnardo M, Lincoln M, Ramagopalan S, Herrera B, Dyment D . HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci U S A. 2008; 105(35):13069-74. PMC: 2529028. DOI: 10.1073/pnas.0801042105. View

14.

Barcellos L, Sawcer S, Ramsay P, Baranzini S, Thomson G, Briggs F . Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006; 15(18):2813-24. DOI: 10.1093/hmg/ddl223. View

15.

Rioux J, Goyette P, Vyse T, Hammarstrom L, Fernando M, Green T . Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A. 2009; 106(44):18680-5. PMC: 2773992. DOI: 10.1073/pnas.0909307106. View

16.

Sombekke M, Lukas C, Crusius J, Tejedor D, Killestein J, Arteta D . HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol. 2009; 66(12):1531-6. DOI: 10.1001/archneurol.2009.278. View

17.

Lorentzen A, Karlsen T, Olsson M, Smestad C, Mero I, Woldseth B . Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol. 2009; 65(6):658-66. DOI: 10.1002/ana.21695. View

18.

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

19.

McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. DOI: 10.1002/ana.1032. View

20.

Baranzini S, Wang J, Gibson R, Galwey N, Naegelin Y, Barkhof F . Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2008; 18(4):767-78. PMC: 4334814. DOI: 10.1093/hmg/ddn388. View